Shares of other companies:
A.O. Smith: Great Company, Inferior Investment
May 18, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
ALLO Stock News and Mentions of Allogene Therapeutics, Inc. Stocktwits
Updated: May 19, 2024 (14:26)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Allogene Therapeutics Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Allogene Therapeutics, Inc. (ALLO).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Allogene Therapeutics stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Allogene Therapeutics, Inc. (ALLO)
May 15, 2024 (12:14) / "Benzinga" (by Avi Kapoor)
Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket - Arcutis Biotherapeutics ( NASDAQ:ARQT )
Shares of Arcutis Biotherapeutics, Inc. ARQT rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results. Arcutis Biotherapeutics reported quarterly earnings of 32 cents per share which beat the analyst consensus estimate of losses of ...
In Article Trend: Neutral
May 15, 2024 (10:12) / "Benzinga" (by Avi Kapoor)
DLocal, Allogene Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - DLocal ( NASDAQ:DLO )
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 20 points on Wednesday. Shares of DLocal Limited DLO fell sharply in today's pre-market trading after the company reported weaker-than-expected first-quarter earnings and said there is a greater likelihood ...
In Article Trend: Neutral
May 14, 2024 (16:56) / "Zacks Commentary" (by Zacks Equity Research)
Allogene ( ALLO ) Q1 Earnings in Line With Estimates, Sales Lag
Allogene (ALLO) reports drab first-quarter 2024 results. The company secures the development and marketing rights to its CD19 oncology program in Europe.
In Article Trend: Neutral
May 13, 2024 (21:10) / "Zacks Commentary" (by Zacks Equity Research)
Allogene Therapeutics ( ALLO ) Reports Q1 Loss, Lags Revenue Estimates
Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 0% and 47.62%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
May 13, 2024 (20:47) / "GlobeNewswire" (by Inc.)
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., May 13, 2024 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics, Inc. ( Nasdaq: ALLO ) , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ( AlloCAR T™ ) products for cancer and autoimmune disease, today announced the pricing of an ...
In Article Trend: Neutral
May 10, 2024 (13:51) / "Zacks Commentary" (by Zacks Equity Research)
CollPlant Biotechnologies ( CLGN ) Soars 8.2%: Is Further Upside Left in the Stock?
CollPlant Biotechnologies (CLGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
In Article Trend: Somewhat-Bullish
May 9, 2024 (21:25) / "Zacks Commentary" (by Zacks Equity Research)
Fate Therapeutics ( FATE ) Reports Q1 Loss, Tops Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 0% and 140.63%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
May 8, 2024 (22:05) / "Zacks Commentary" (by Zacks Equity Research)
Exact Sciences ( EXAS ) Reports Q1 Loss, Tops Revenue Estimates
Exact Sciences (EXAS) delivered earnings and revenue surprises of 0% and 2.01%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
May 6, 2024 (12:30) / "Benzinga" (by Globe Newswire)
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update - Allogene Therapeutics ( NASDAQ:ALLO )
Conference Call and Webcast Scheduled for May 13, 2024 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2024 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics, Inc.
In Article Trend: Neutral
April 26, 2024 (12:30) / "GlobeNewswire" (by Inc.)
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
SOUTH SAN FRANCISCO, Calif., April 26, 2024 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics, Inc. ( Nasdaq: ALLO ) , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ( AlloCAR T™ ) products for cancer and autoimmune disease, announced that it has received a $15 ...
In Article Trend: Somewhat-Bullish
April 25, 2024 (14:02) / "Zacks Commentary" (by Zacks Equity Research)
Omega Therapeutics, Inc. ( OMGA ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Omega Therapeutics (OMGA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Somewhat-Bullish
April 24, 2024 (14:01) / "Zacks Commentary" (by Zacks Equity Research)
Allogene Therapeutics ( ALLO ) Expected to Beat Earnings Estimates: Should You Buy?
Allogene Therapeutics (ALLO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Neutral
April 8, 2024 (12:46) / "Zacks Commentary" (by Zacks Equity Research)
How Allogene ( ALLO ) Stock Stands Out in a Strong Industry
Allogene (ALLO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
In Article Trend: Bullish
Related stocks from Healthcare sector
Alnylam Pharmaceuticals, Inc. (ALNY)
Allied Healthcare Products, Inc. (AHPI)
Catalent, Inc. (CTLT)
Genprex, Inc. (GNPX)
Kiniksa Pharmaceuticals, Ltd. (KNSA)
IMAC Holdings, Inc. (IMAC)
electroCore, Inc. (ECOR)
EyePoint Pharmaceuticals, Inc. (EYPT)
Galera Therapeutics, Inc. (GRTX)
Arbutus Biopharma Corp. (ABUS)
This website uses cookies to ensure you get the best experience on our website